Floatz logo

Lurbinectedin

Gastric Carcinoma

PharmaMarSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

49 Active assets in the Gastric Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
City of Hope Medical Center
Phase 1/2CCC
gsk1120212
National Cancer Institute (NCI)
Phase 2CCC
Dabrafenib
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Gdc-0449
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Lurbinectedin is also rated in:

Small-cell Lung CancerDormant
BBB
Indicative ·
72 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
small cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →